Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $11.50.

A number of brokerages recently commented on KPTI. Wall Street Zen downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Robert W. Baird lowered Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 target price for the company. in a report on Friday, July 31st. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $16.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, July 21st. HC Wainwright lowered Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research report on Friday, July 31st. Finally, Weiss Ratings cut Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th.

Karyopharm Therapeutics Price Performance

Shares of KPTI stock opened at $0.35 on Tuesday. The company has a market cap of $7.85 million, a PE ratio of -0.03 and a beta of 1.04. Karyopharm Therapeutics has a 1 year low of $0.31 and a 1 year high of $10.99. The stock’s 50 day simple moving average is $1.47 and its two-hundred day simple moving average is $5.80.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($2.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.95). The company had revenue of $33.43 million for the quarter, compared to the consensus estimate of $32.19 million. Equities research analysts expect that Karyopharm Therapeutics will post -4.70 EPS for the current year.

Institutional Trading of Karyopharm Therapeutics

A number of institutional investors have recently bought and sold shares of KPTI. Squarepoint Ops LLC purchased a new stake in Karyopharm Therapeutics in the second quarter valued at approximately $623,000. Headlands Technologies LLC purchased a new position in Karyopharm Therapeutics during the 2nd quarter worth approximately $118,000. Bank of New York Mellon Corp acquired a new stake in Karyopharm Therapeutics during the 2nd quarter valued at approximately $559,000. Avidity Partners Management LP lifted its stake in Karyopharm Therapeutics by 244.6% during the 1st quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock valued at $2,583,000 after acquiring an additional 329,175 shares during the period. Finally, Royal Bank of Canada lifted its stake in Karyopharm Therapeutics by 4.1% during the 1st quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock valued at $336,000 after acquiring an additional 2,399 shares during the period. 66.44% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a commercial-stage biopharmaceutical company focused on discovering and developing medicines that target nuclear transport proteins involved in cancer and other serious diseases. The company’s technology platform centers on selective inhibitors of nuclear export, particularly exportin 1 (XPO1), a protein that helps regulate the movement of key molecules between a cell’s nucleus and cytoplasm.

Karyopharm’s primary product is XPOVIO (selinexor), an oral XPO1 inhibitor.